Company Overview and News
2018-09-19 investorplace - 1
Editor’s note: This column is part of our Best Stocks for 2018 contest. Charles Sizemore’s pick for the contest is Enterprise Products Partners (NYSE:EPD).
AMZN EPD CMG ETSY
2018-09-19 investorplace - 1
Amazon (NASDAQ:AMZN) wants you to know that they aren’t killing small retailers. Instead, they are enabling them and helping bolster Amazon stock at the same time.
SHOP AMZN ETSY
2018-09-14 investorplace - 1
A new round of tariffs sucked the wind out of the markets on Friday, but not enough to snowball any sort of large declines into the weekend. U.S. equities traded around flat on Friday, surprising given the decent rally we’ve had this week. Let’s look at our top stock trades.
SHLD GE GEC KR AAPL GNE SHLDW ETSY
On today’s episode of Free Lunch, Associate Stock Strategist Ryan McQueeney highlights the latest bullish analyst note about AMD. He also recaps news related to Netflix, Etsy, and Tailored Brands. Later, he reviews Apple’s iPhone reveal event and checks in on the stock’s earnings fundamentals.
AAPL NFLX OXY TLRD ETSY
Etsy Inc. ETSY, -0.47% said Thursday that Chief Operating Officer Linda Findley Kozlowski will leave the company at the end of the year, to pursue other opportunities. Shares of the online marketplace for handmade products edged up 0.2% in premarket trade. The company said it does not plan to refill the COO role after Kozlowski leaves. "We have a strong bench of talent, and I plan to devote more time to working directly with our product teams so that we can execute on our roadmap and drive growth," said Chief Executive Josh Silverman.
Etsy Inc. ETSY, -0.47% said Thursday that its chief operating officer has resigned from the company. COO Linda Findley Kozlowski is stepping down to "pursue other opportunities," though she will stay with the company through the end of the year, the company said in a release. Etsy said that it "does not currently intend to refill the COO role following Linda's departure." Shares are down 1.1% in premarket trading, though they're up 176% over the past 12 months.
Facebook’s (FB - Free Report) Instagram is reportedly set to roll out a shopping app. Per The Verge, the app, which will most likely be named IG Shopping, is in the test phase. Facebook is increasingly trying to diversify its revenue streams from a traditional ad-based business model. The company has been ramping up efforts to bring in new features to extend its offerings in various categories including e-commerce.
FB SHOP KHC MELI ETSY
2018-08-30 investorplace - 1
Shares of streaming device maker Roku (NASDAQ:ROKU) dropped sharply on reports that ecommerce and cloud behemoth Amazon (NASDAQ:AMZN) is launching a free, ad-supported video streaming service which would be in direct competition with The Roku Channel, one of Roku’s biggest growth drivers. The news didn’t help Roku stock at all.
W AMZN ROKU ETSY
2018-08-27 reuters - 1
WASHINGTON (Reuters) - A coalition of trade groups representing companies including Alphabet Inc, Facebook Inc and Amazon.com Inc, urged a U.S. appeals court to reinstate landmark “net neutrality” rules adopted in 2015 to guarantee an open internet.
FB CCV CMCSA NFLX CCZ GOOG VZA CCV.CL GOOGL TWTR VZ MSFT CMCSK ETSY
Investors interested in stocks from the Internet - Services sector have probably already heard of Internet Initiative Japan (IIJI - Free Report) and Etsy (ETSY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
3774 IIJI IIJIF ETSY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET